Proactive Investors - Run By Investors For Investors

Benchmark shrugs off challenging shrimp market to deliver earnings growth

Benchmark expects full-year results to be broadly in line with market forecasts
The salmon market has seen growing demand and stable prices

Aquaculture and genetics firm Benchmark Holdings PLC (LON:BMK) said it was on track to meet its strategy goals as it shrugged off a challenging shrimp market to deliver a 25% rise in first-half earnings.

In the six months ended March 31, adjusted earnings (EBITDA) rose to £7.5mln from £6.0mln a year ago as revenue increased 3% to £78.3mln.

A strong performance in the genetics division offset lower revenue in the advanced nutrition business, which was hit by a tough shrimp market.

Benchmark said conditions in its core markets remain mixed with salmon seeing growing demand and stable prices but the shrimp market seeing depressed prices and a drop in production due to overstocking.

"We have delivered growth in adjusted EBITDA and made progress against our strategic priorities despite challenging conditions in the shrimp markets,” said chief executive Malcolm Pye.

“We continue to implement operational and structural efficiency initiatives and we expect the group to deliver broadly in line with market expectations for the full year.”

Pye added that the company has started to see the benefits from its investments, including the opening of a new facility in Salten, Norway, which has been well-received by customers.

He said these investments, combined with the successful completion of a refinancing on Monday, leaves Benchmark well placed to deliver on its five-year strategy to drive future growth and profitability.

View full BMK profile View Profile

Benchmark Holdings PLC Timeline

July 09 2019

Related Articles

A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
test tubes
May 02 2019
Proactive takes a closer look at an innovative drugs company that has largely flown under the radar
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use